This study encompassed a comprehensive set of variables, including those related to socioeconomic factors and key comorbidities
At Urban You, we specialize in personalized regenerative medicine and aesthetic wellness
More than a third of subjects in the semaglutide arm of the study lost more than 20% of their weight
Semaglutide (Ozempic/Wegovy/Rybelsus) is approved across 30 disease areas including T2D, obesity, cardiovascular disease, MASH, pulmonary fibrosis, and CKD
The primary drivers behind this effect are a group of antioxidants known as polyphenols, specifically a catechin called epigallocatechin gallate (EGCG)
Over time, potential benefits may include continued fat loss, improved metabolic health, better weight maintenance, and greater confidence and quality of life